Analysts Issue Forecasts for Organogenesis FY2025 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Organogenesis in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings of ($0.08) per share for the year. The consensus estimate for Organogenesis’ current full-year earnings is ($0.07) per share.

Organogenesis Stock Up 0.9 %

Shares of NASDAQ:ORGO opened at $3.53 on Thursday. Organogenesis has a 1 year low of $2.16 and a 1 year high of $4.57. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The business’s 50-day moving average is $3.48 and its 200-day moving average is $3.11. The company has a market capitalization of $443.83 million, a price-to-earnings ratio of -58.83 and a beta of 1.77.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same quarter last year, the firm earned $0.02 earnings per share.

Institutional Trading of Organogenesis

Large investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its holdings in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock worth $9,443,000 after acquiring an additional 1,035,120 shares in the last quarter. AQR Capital Management LLC grew its position in Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares during the period. Dimensional Fund Advisors LP raised its holdings in Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after buying an additional 333,123 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Organogenesis by 107.8% in the third quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company’s stock valued at $589,000 after buying an additional 106,823 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Organogenesis by 1,350.3% during the second quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock valued at $265,000 after buying an additional 88,175 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 18,416 shares of Organogenesis stock in a transaction on Friday, December 6th. The shares were sold at an average price of $3.65, for a total value of $67,218.40. Following the completion of the sale, the chief executive officer now directly owns 3,400,778 shares of the company’s stock, valued at approximately $12,412,839.70. The trade was a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 278,116 shares of company stock valued at $991,190. 36.90% of the stock is currently owned by company insiders.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.